Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients

[1]  笠ゆりな,et al.  myelodysplastic syndrome(MDS)に合併したsubcutaneous Sweet’s syndromeの1例 , 2016 .

[2]  P. Atadja,et al.  Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies , 2013, Leukemia.

[3]  E. Campo,et al.  The genomic landscape of chronic lymphocytic leukemia: clinical implications , 2013, BMC Medicine.

[4]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[5]  P. Zinzani,et al.  Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[7]  S. Lonial,et al.  Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes , 2011, Leukemia.

[8]  Magnus Isaksson,et al.  Targeted resequencing of candidate genes using selector probes , 2010, Nucleic Acids Res..

[9]  J. Dipersio,et al.  Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS) , 2011, Annals of Hematology.

[10]  M. Lübbert,et al.  Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy , 2010, Clinical Epigenetics.

[11]  M. Gobbi,et al.  Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes , 2009, Clinical Cancer Research.

[12]  R. Johnstone,et al.  Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. , 2009, Future oncology.

[13]  A. Stamatoullas,et al.  Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases , 2009, Leukemia.

[14]  Jorge Cortes,et al.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.

[15]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[16]  C. Steidl,et al.  Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia , 2005, Annals of Hematology.

[17]  I. Dybedal,et al.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.

[18]  P. Greenberg,et al.  Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.